中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2164-2167

Hepatitis flare and treatment in postpartum women with chronic hepatitis B virus infection

DOI: 10.12449/JCH241106

  • Department of Infectious Diseases，Shengjing Hospital of China Medical University，Shenyang 110022，China

Research funding:

Applied Basic Research Program of Liaoning Science and Technology Department (2022JH2/101500009)

More Information
  • Corresponding author: DING Yang， yding0903@sina.com （ORCID： 0000-0002-7066-2865）
  • Received Date: 2024-09-01
  • Accepted Date: 2024-09-20
  • Published Date: 2024-11-25
    Abstract
  • Hepatitis flare can happen in postpartum women with chronic hepatitis B virus （HBV） infection due to the changes in immune function and hormone levels. In order to delay disease progression in parturients and ensure the safety of mothers and infants， it is crucial to strengthen the monitoring of liver function， serum HBV markers， and HBV DNA in postpartum women with chronic HBV infection and optimize the strategies for antiviral therapy. This article elaborates on the clinical features， pathogenesis， predictive factors， and treatment strategies for hepatitis flare in postpartum women with chronic HBV infection， in order to help clinicians with the monitoring and treatment of hepatitis flare in postpartum women with chronic HBV infection.

     

    • FullText(HTML)
  • loading
    • References(37)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. uidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.1
    [2]
    CUI FQ, WOODRING J, CHAN PL, et al. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China[J]. Int J Epidemiol, 2018, 47( 5): 1529- 1537. DOI: 10.1093/ije/dyy077.
    [3]
    Chinese Society of Hepatology, Chinese Medical Association. Consensus on the management of hepatitis B virus infection in women of childbearing age[J]. J Clin Hepatol, 2018, 34( 6): 1176- 1180. DOI: 10.3969/j.issn.1001-5256.2018.06.008.

    中华医学会肝病学分会. 感染乙型肝炎病毒的育龄女性临床管理共识[J]. 临床肝胆病杂志, 2018, 34( 6): 1176- 1180. DOI: 10.3969/j.issn.1001-5256.2018.06.008.
    [4]
    Chinese Foundation for Hepatitis Prevention and Control; Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Management algorithm for interrupting mother-to-child transmission of hepatitis B virus(2021)[J]. J Clin Hepatol, 2021, 37( 3): 527- 531. DOI: 10.3969/j.issn.1001-5256.2021.03.007.

    中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会. 阻断乙型肝炎病毒母婴传播临床管理流程(2021年)[J]. 临床肝胆病杂志, 2021, 37( 3): 527- 531. DOI: 10.3969/j.issn.1001-5256.2021.03.007.
    [5]
    HAN GR, CAO MK, ZHAO W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol, 2011, 55( 6): 1215- 1221. DOI: 10.1016/j.jhep.2011.02.032.
    [6]
    GILES M, VISVANATHAN K, LEWIN S, et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B[J]. Gut, 2015, 64( 11): 1810- 1815. DOI: 10.1136/gutjnl-2014-308211.
    [7]
    PAN CQ, DUAN ZP, DAI EH, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374( 24): 2324- 2334. DOI: 10.1056/NEJMoa1508660.
    [8]
    LIU JF, WANG J, JIN DF, et al. Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus[J]. J Gastroenterol Hepatol, 2017, 32( 1): 177- 183. DOI: 10.1111/jgh.13436.
    [9]
    ZHAO MY, ZOU HB, CHEN Y, et al. Characteristics and mechanism of virological and liver function changes in pregnant women with chronic hepatitis B virus infection during pregnancy and after delivery[J]. J Clin Hepatol, 2019, 35( 6): 1353- 1357. DOI: 10.3969/j.issn.1001-5256.2019.06.038.

    赵梦鱼, 邹怀宾, 陈煜, 等. 慢性HBV感染孕妇妊娠期及分娩后病毒学和肝功能变化的特点及机制[J]. 临床肝胆病杂志, 2019, 35( 6): 1353- 1357. DOI: 10.3969/j.issn.1001-5256.2019.06.038.
    [10]
    BORG MJ TER, LEEMANS WF, de MAN RA, et al. Exacerbation of chronic hepatitis B infection after delivery[J]. J Viral Hepat, 2008, 15( 1): 37- 41. DOI: 10.1111/j.1365-2893.2007.00894.x.
    [11]
    LIN HH, WU WY, KAO JH, et al. Hepatitis B post-partum e antigen clearance in hepatitis B carrier mothers: Correlation with viral characteristics[J]. J Gastroenterol Hepatol, 2006, 21( 3): 605- 609. DOI: 10.1111/j.1440-1746.2006.04198.x.
    [12]
    ZENG Z, ZHOU MF, LIN YJ, et al. A real-world study on the features of postpartum hepatitis flares in pregnant women with chronic HBV infection[J]. Chin J Hepatol, 2024, 32( 2): 113- 118. DOI: 10.3760/cma.j.cn501113-20231122-00216.

    曾湛, 周明芳, 林妍洁, 等. 慢性HBV感染孕妇分娩后肝炎发作特点的真实世界研究[J]. 中华肝脏病杂志, 2024, 32( 2): 113- 118. DOI: 10.3760/cma.j.cn501113-20231122-00216.
    [13]
    WANG XX, SONG AX, LIN X, et al. Clinical characteristics of hepatitis flares during pregnancy and postpartum in Chinese chronic hepatitis B virus carriers-a prospective cohort study of 417 cases[J]. Front Immunol, 2022, 13: 1031291. DOI: 10.3389/fimmu.2022.1031291.
    [14]
    ZHANG L, JIANG TT, YANG Y, et al. Postpartum hepatitis and host immunity in pregnant women with chronic HBV infection[J]. Front Immunol, 2023, 13: 1112234. DOI: 10.3389/fimmu.2022.1112234.
    [15]
    SONG AX, LIU YS, CAO ZH, et al. Clinical features and T cell immune characteristics of postpartum hepatitis flare in pregnant women with HBeAg-positive chronic HBV infection[J]. Front Immunol, 2022, 13: 881321. DOI: 10.3389/fimmu.2022.881321.
    [16]
    HUANG MT, GAO YF, YIN XR, et al. Characterization of T cell immunity in chronic hepatitis B virus-infected mothers with postpartum alanine transaminase flare[J]. BMC Infect Dis, 2021, 21( 1): 922. DOI: 10.1186/s12879-021-06634-2.
    [17]
    NGUYEN V, TAN PK, GREENUP AJ, et al. Anti-viral therapy for prevention of perinatal HBV transmission: Extending therapy beyond birth does not protect against post-partum flare[J]. Aliment Pharmacol Ther, 2014, 39( 10): 1225- 1234. DOI: 10.1111/apt.12726.
    [18]
    KIM HY, CHOI JY, PARK CH, et al. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus[J]. J Clin Virol, 2013, 56( 4): 299- 305. DOI: 10.1016/j.jcv.2012.11.019.
    [19]
    QUAN M, LIU XM, LIU C, et al. Antiviral therapy for prevention of perinatal hepatitis B virus transmission reduces the incidence of postpartum hepatitis flare[J]. Biomed Res Int, 2022, 2022: 7046955. DOI: 10.1155/2022/7046955.
    [20]
    SAMADI KOCHAKSARAEI G, SHAHEEN AA, SEOW CH, et al. Tenofovir disoproxil fumarate therapy to prevent hepatitis B virus vertical transmission-a review of maternal and infant outcomes[J]. Liver Int, 2022, 42( 8): 1712- 1730. DOI: 10.1111/liv.15249.
    [21]
    QUAN M, LIU C, LI W, et al. Antiviral therapy for a postpartum flare in women with chronic HBV infection shortens the ALT recovery time and reduces hepatitis re-flare rates within 4 years[J]. Can J Gastroenterol Hepatol, 2022, 2022: 4753267. DOI: 10.1155/2022/4753267.
    [22]
    YI W, PAN CQ, LI MH, et al. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B[J]. Am J Gastroenterol, 2018, 113( 5): 686- 693. DOI: 10.1038/s41395-018-0010-2.
    [23]
    CHANG CY, AZIZ N, POONGKUNRAN M, et al. Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B[J]. Am J Gastroenterol, 2016, 111( 10): 1410- 1415. DOI: 10.1038/ajg.2016.296.
    [24]
    LI L, XU MM, ZOU HB, et al. Meta-analysis of the risk for abnormal liver function in pregnancy with high HBV DNA after antiviral therapy withdrawal[J]. Altern Ther Health Med, 2023, 29( 1): 280- 288.
    [25]
    ZENG QL, XU GH, WANG B, et al. Prophylactic antiviral therapy for the prevention of mother-to-child transmission of hepatitis B virus can be stopped at delivery[J]. J Viral Hepat, 2018, 25( 5): 612- 613. DOI: 10.1111/jvh.12848.
    [26]
    XIAO LX, CHEN YR, HUANG P, et al. The safety of antiviral therapy and drug withdrawal for the prevention of mother-to-child transmission of HBV during pregnancy[J]. J Med Virol, 2020, 92( 12): 3381- 3389. DOI: 10.1002/jmv.26011.
    [27]
    LI MH, SUN FF, BI XY, et al. Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection[J]. Hepatol Int, 2023, 17( 1): 42- 51. DOI: 10.1007/s12072-022-10412-w.
    [28]
    CHEN Y, MAK LY, TANG MHY, et al. Immediate postpartum cessation of tenofovir did not increase risk of virological or clinical relapse in highly viremic pregnant mothers with chronic hepatitis B infection[J]. JHEP Rep, 2024, 6( 5): 101050. DOI: 10.1016/j.jhepr.2024.101050.
    [29]
    SAMADI KOCHAKSARAEI G, CASTILLO E, SADLER MD, et al. Real-world clinical and virological outcomes in a retrospective multiethnic cohort study of 341 untreated and tenofovir disoproxil fumarate-treated chronic hepatitis B pregnant patients in North America[J]. Aliment Pharmacol Ther, 2020, 52( 11-12): 1707- 1716. DOI: 10.1111/apt.16123.
    [30]
    LIU RY, YANG L, JIANG TT, et al. Hepatitis B core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic HBV infection after short-course antiviral therapy[J]. Virulence, 2023, 14( 1): 2186335. DOI: 10.1080/21505594.2023.2186335.
    [31]
    LI L, ZOU HB, XU MM, et al. Risk factors related to postpartum hepatic inflammation in pregnant women with chronic hepatitis B[J]. J Int Med Res, 2020, 48( 11): 300060520966439. DOI: 10.1177/0300060520966439.
    [32]
    Infectious Diseases Physicians Branch, Chinese Medical Doctor Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese practice guideline for the prevention and treatment of mother-to-child transmission of hepatitis B virus(version 2024)[J]. J Clin Hepatol, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809.

    中国医师协会感染科医师分会, 中华医学会感染病学分会. 中国乙型肝炎病毒母婴传播防治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809.
    [33]
    TRAN TT, AHN J, REAU NS. ACG clinical guideline: Liver disease and pregnancy[J]. Am J Gastroenterol, 2016, 111( 2): 176- 194;quiz196. DOI: 10.1038/ajg.2015.430.
    [34]
    FENG YL, YAO NJ, SHI L, et al. Efficacy and safety of long-term postpartum antiviral therapy in hepatitis B virus-infected mothers receiving prophylactic tenofovir disoproxil fumarate treatment[J]. Eur J Gastroenterol Hepatol, 2023, 35( 2): 212- 218. DOI: 10.1097/MEG.0000000000002476.
    [35]
    CHEN XY, WANG XX. Management of liver dysfunction during pregancy and postpartum in pregnant women who are chronic carriers of hepatitis B virus[J]. Chin J Hepatol, 2019, 27( 2): 88- 91. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.003.

    陈新月, 王晓晓. 慢性乙型肝炎病毒携带孕妇妊娠及产后肝功能异常及其管理[J]. 中华肝脏病杂志, 2019, 27( 2): 88- 91. DOI: 10.3760/cma.j.issn.1007-3418.2019.02.003.
    [36]
    LU JF, ZHANG SB, LIU YL, et al. Effect of Peg-interferon α-2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA[J]. Liver Int, 2015, 35( 6): 1692- 1699. DOI: 10.1111/liv.12753.
    [37]
    ZHONG WT, YAN LZ, ZHU YG, et al. A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: An exploratory study[J]. Front Cell Infect Microbiol, 2024, 14: 1426960. DOI: 10.3389/fcimb.2024.1426960.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (123) PDF downloads(42) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return